Dose Intensity in Real-World Patients With Metastatic Renal Cell Carcinoma Taking Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors

Wiechno, 2018, Contemporary treatment of metastatic renal cell carcinoma, Med Oncol, 35, 156, 10.1007/s12032-018-1217-1 Zerdes, 2019, Systemic therapy of metastatic renal cell carcinoma: review of the current literature, Urologia, 86, 3, 10.1177/0391560318802166 Fishman, 2015, A systematic review of the efficacy and safety experience reported for sorafenib in advanced renal cell carcinoma (RCC) in the post-approval setting, PLoS One, 10, 10.1371/journal.pone.0120877 Porta, 2016, Long-term safety of sunitinib in metastatic renal cell carcinoma, Eur Urol, 69, 345, 10.1016/j.eururo.2015.07.006 Choueiri, 2017, Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: the alliance A031203 CABOSUN trial, J Clin Oncol, 35, 591, 10.1200/JCO.2016.70.7398 Rini, 2011, Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial, Lancet, 378, 1931, 10.1016/S0140-6736(11)61613-9 Motzer, 2015, Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial, Lancet Oncol, 16, 1473, 10.1016/S1470-2045(15)00290-9 Choueiri, 2016, Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial, Lancet Oncol, 17, 917, 10.1016/S1470-2045(16)30107-3 Powles, 2020, Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial, The Lancet Oncology, 21, 1563, 10.1016/S1470-2045(20)30436-8 Escudier, 2014, Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES study, J Clin Oncol, 32, 1412, 10.1200/JCO.2013.50.8267 Motzer, 2012, Randomized, open-label, phase III trial of pazopanib versus sunitinib in first-line treatment of patients with metastatic renal cell carcinoma (MRCC): results of the comparz trial, Ann Oncol, 23, ixe13, 10.1016/S0923-7534(20)34325-8 Motzer, 2021, Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma, N Engl J Med, 384, 1289, 10.1056/NEJMoa2035716 Ishihara, 2018, Decreased relative dose intensity during the early phase of treatment impacts the therapeutic efficacy of sunitinib in metastatic renal cell carcinoma, Jpn J Clin Oncol, 48, 667, 10.1093/jjco/hyy078 Kennedy-Martin, 2015, A literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial results, Trials, 16, 495, 10.1186/s13063-015-1023-4 Motzer, 2013, Pazopanib versus Sunitinib in metastatic renal-cell carcinoma, N Engl J Med, 369, 722, 10.1056/NEJMoa1303989 McElwee, 2020, Cabozantinib use in metastatic renal cell carcinoma patients in clinical practice: evaluation of dosing patterns, tolerability, and outcomes compared to clinical trials, J Oncol Pharm Pract, 26, 861, 10.1177/1078155219875509 Albiges, 2021, Real-world evidence of cabozantinib in patients with metastatic renal cell carcinoma: results from the CABOREAL early access program, Eur J Cancer, 142, 102, 10.1016/j.ejca.2020.09.030 Choueiri, 2021, Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma, N Engl J Med, 384, 829, 10.1056/NEJMoa2026982 Pal, 2022, Assessing the safety and efficacy of two starting doses of lenvatinib plus everolimus in patients with renal cell carcinoma: a randomized phase 2 trial, Eur Urol, 82, 283, 10.1016/j.eururo.2021.12.024